Navigation Links
Kosan Biosciences to Host Research & Development Day on October 31, 2007
Date:10/25/2007

HAYWARD, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Inc. (Nasdaq: KOSN) today announced that it will host a Research and Development Day on Wednesday, October 31, 2007, beginning at approximately 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time). In addition to presentations by Kosan's Executives, Robert G. Johnson, Jr., M.D., Ph.D., President and Chief Executive Officer and Pieter Timmermans, Ph.D., Senior Vice President, Drug Discovery and Preclinical Development, invited guest speakers include key oncology opinion leaders.

-- Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine at

Harvard Medical School, Chief of the Division of Hematologic Neoplasia,

Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair

of the Joint Program in Transfusion Medicine at Dana-Farber Cancer

Institute

-- Howard (Skip) A. Burris III, M.D., F.A.C.P., Chief Medical Officer and

Director, Drug Development at Sarah Cannon Research Institute

-- Clifford A. Hudis, M.D., Chief of the Breast Cancer Medicine Service

and Attending Physician at Memorial Sloan-Kettering Cancer Center and

Associate Professor of Medicine at Weill Medical College of Cornell

University

-- Neal Rosen, M.D, Ph.D., Enid A. Haupt Chair in Medical Oncology,

Member, Department of Medicine and Program in Molecular Pharmacology

and Chemistry, Head, Developmental Therapeutics at Memorial

Sloan-Kettering Cancer Center

A live audio webcast of the presentation will be available at http://www.kosan.com on the "Investors/Press" page under "Upcoming Events" or by clicking on the "Events Calendar" tab under the same heading, "Investors/Press." A replay of the presentation will be available for 30 days following event. Please connect to Kosan's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical

trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
(Date:10/5/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... back to cancer research with a month-long promotion supporting the advancement of breast cancer ... can use promo code PinkRibbon to get 10 percent off their purchase of every ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):